



Dexcom, Inc. | Corporate Headquarters
6340 Sequence Drive
San Diego, CA 92121
888.738.3646
dexcom.com

March 3, 2025

House Behavioral Health and Health Care Committee
900 Court St.
Salem, OR 97301

RE: SUPPORT for HB 2955 Continuous Glucose Monitoring (CGM) Systems

Chair Nosse and House Health Committee:

Dexcom is pleased to provide this written submission in support of Representative Tran's HB 2955 (including proposed amendments to include gestational diabetes) and urges the committee's support.

Founded in 1999 and based in San Diego, Dexcom, Inc. is the market leader in transforming diabetes care and management by providing superior continuous glucose monitoring (CGM) technology to help patients and healthcare professionals better manage diabetes¹. CGM technologies allow individuals with diabetes to track their glucose levels at regular intervals throughout the day and night and help patients with diabetes more accurately dose insulin. According to the American Diabetes Association, CGMs are today's recognized Standard of Medical Care for effective diabetes treatment for those patients on insulin therapy.

Patients with better management of their diabetes have better outcomes, a higher quality of life and cost significantly less to the state. Without proper care, diabetes patients are at increased risk of blindness, limb amputation, kidney failure and heart disease. These complications lead to a significant impact on healthcare utilization and costs. Real time CGM systems have been proven to improve glucose control through reductions in HbA1c and time spent in hypoglycemia. These improvements have been demonstrated for patients on insulin therapy regardless of one's education level, income, age or math ability². The alerts, alarms and share feature of real-time therapeutic CGM systems help address hypoglycemia and are extremely important in saving lives and saving money with reduced hospitalizations.

Approximately 306,000 Oregonians (nearly 10% of the state's population) live with diabetes. Along with the increasing prevalence of diabetes in the state, medical expenditures related to this disease continue to rise, with diagnosed diabetes costing an estimated \$4.3 billion in Oregon each year.⁵ Oregon **Medicaid patients do not have equitable access to diabetes technologies that are necessary to best manage their diabetes.**

Medicare, most commercial plans and almost all state Medicaid programs cover CGMs for ALL patients with diabetes on insulin. While we commend the Oregon Health Authority for updating its coverage policy in January 2024, they still do not meet the Standards of Care for patients with diabetes

on insulin, resulting in disparate access for Oregon patients with diabetes on Medicaid. This bill will bring Oregon Medicaid CGM coverage policy in line with Medicare coverage policy and provide equitable cover for those Oregon patients with diabetes on Medicaid.


According to the US Preventive Services Task Force, the presence of uncontrolled gestational diabetes is associated with several poor health outcomes, including increased risk of cesarean delivery, fetal macrosomia birth injuries and neonatal intensive care unit admissions (NICU). Studies show that at or after 24 weeks of gestation treatment of gestational diabetes, including more carefully checking blood glucose levels, was significantly associated with improved health outcomes for both mom and baby.³ Studies also show that CGMs may help women achieve glucose goals and reduce hypoglycemia.⁴

Over half of state Medicaid programs offer CGM coverage for women diagnosed with Gestational Diabetes, with several more doing so in the next several months.

With the proven improvements in patient health outcomes associated with CGMs and the corresponding financial savings opportunities, Dexcom strongly supports HB 2955 and the proposed amendments.

We respectfully urge your support of HB 2955 as amended which will provide needed coverage of CGMs for Oregon Medicaid enrollees.

Sincerely,

A handwritten signature in blue ink, reading "Dee Ann Stahly". The signature is written in a cursive, flowing style.

Dee Ann Stahly
Director, State Government Affairs
Dexcom, Inc.

References

1. See <https://www.dexcom.com/about-dexcom>
2. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. *Jama*. 2017;317(4):371-378.
3. <https://www.uspreventiveservicetaskforce.org/uspsf/document/final-evidence-summary/gestationaldiabetes-screening>.
4. <https://pubmed.ncbi.nlm.nih.gov/28585876/>.
5. http://main.diabetes.org/dorg/docs/state-fact-sheets/ADV_2020_State_Fact_sheet_OR.pdf.